Medicare launches $50/month GLP-1 weight loss drug program

The Trump administration has launched a temporary Medicare Bridge program to provide some beneficiaries with access to popular weight loss medications like tirzepatide and semaglutide for a flat $50 monthly co-payment. This program, running until December 2027, bypasses traditional Medicare Part D coverage restrictions for weight loss drugs. While aiming to increase affordability, concerns remain about the $50 cost being a barrier for low-income individuals and the program's uncertain future beyond its expiration date. AI

RANK_REASON Policy change enabling access to a new class of drugs for a large population. [lever_c_demoted from significant: ic=1 ai=0.0]

Read on Forbes — Innovation →

• BALANCE
• Centers for Medicare and Medicaid Services
• Foundayo
• GLP-1
• Medicare
• orforglipron
• semaglutide
• tirzepatide
• Trump administration
• Wegovy

• policy
• product

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →